Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other financing activities (2021 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other financing activities for 4 consecutive years, with $63000.0 as the latest value for Q1 2025.

  • Quarterly Other financing activities fell 91.6% to $63000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $63000.0 through Dec 2025, down 95.05% year-over-year, with the annual reading at $63000.0 for FY2025, 95.05% down from the prior year.
  • Other financing activities for Q1 2025 was $63000.0 at Akebia Therapeutics, down from $522000.0 in the prior quarter.
  • The five-year high for Other financing activities was $44.8 million in Q2 2021, with the low at $63000.0 in Q1 2025.
  • Average Other financing activities over 4 years is $17.2 million, with a median of $750000.0 recorded in 2024.
  • Peak annual rise in Other financing activities hit 91.6% in 2025, while the deepest fall reached 91.6% in 2025.
  • Over 4 years, Other financing activities stood at $44.8 million in 2021, then dropped by 10.68% to $40.0 million in 2022, then tumbled by 98.7% to $522000.0 in 2024, then plummeted by 87.93% to $63000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $63000.0, $522000.0, and $750000.0 for Q1 2025, Q3 2024, and Q1 2024 respectively.